Retatrutide 60mg (2x30mg)

Retatrutide 60mg (2x30mg) is a next-generation peptide acting as a triple agonist of the GLP-1, GIP, and glucagon receptors. It is currently being studied for its advanced effects on weight management, glucose regulation, and body composition optimization.

By simultaneously activating these three metabolic pathways, retatrutide may significantly reduce appetite, improve satiety, slow gastric emptying, and increase energy expenditure. Activation of the glucagon receptor may also enhance resting metabolic rate and fat oxidation.

Key Benefits

• Significant appetite suppression

• Major reduction in food cravings and snacking

• Increased satiety and improved portion control

• Increased resting energy expenditure

• Supports body composition optimization

• Improved insulin sensitivity and glucose control

• Optimization of metabolic and lipid markers

• More stable energy levels throughout the day

Typical Injectable Dosage

Subcutaneous injection administered once weekly.

• Common starting dose: 0.5 mg to 1 mg weekly

• Gradual dose escalation based on individual tolerance

• Commonly researched dosages: 2 mg to 8 mg weekly

A slow and progressive increase is generally recommended to optimize overall tolerance.

Important Notice

For research use only. Not intended for human consumption.